Alerta

IMMUNOTHERAPEUTIC CONSTRUCTS AND METHODS OF THEIR USE

Resumen de: US2025195641A1

Disclosed herein are immunotherapeutic constructs comprising a delivery particle, at least one adjuvant, and one or more therapeutic agents/compounds that cause antigen release and/or modulate immunosuppressive tumor microenvironment. These immunotherapeutic constructs create adaptive immunity or anti-cancer immune response(s) that can be used, for instance, to prevent and treat broad types of cancer. Further disclosed are uses of the immunotherapeutic constructs, including to prevent and treat cancer in humans and animals.

MULTI-EPITOPE MRNA SARS-COV-2 VACCINE FOR BOOSTING IMMUNITY THROUGH THE ACTIVATION OF CD4 AND CD8 T CELLS AS WELL AS B LYMPHOCYTES

Resumen de: US2025195639A1

In various embodiments immunogenic nanoparticles are provided that are capable of raising an immune response directed against SARS-CoV-2. In certain embodiments the immunogenic nanoparticles comprise mRNA multi-epitope vaccines that can be used in combination with or independent of other covid-19 vaccines (e.g., the spike protein mRNA vaccine(s)) to invoke a strong CD8+ or CD4+ T-cell as well as neutralizing antibody producing B-cell responses. In certain embodiments this vaccine is based on the rational combination of well-conserved T- and B-cell epitopes identified COVID-19 and viral variants.

METHODS OF TREATING A CANCER IN AN INDIVIDUAL

Resumen de: WO2025129108A1

The present application, in certain aspects, pertains to methods of treating a cancer in an individual using a composition comprising nanoparticles comprising an mTOR inhibitor (such as sirolimus) and an albumin. In some aspects, the methods are directed to an individual subjected to two or more prior treatments. In other aspects, the methods are directed to a cancer of the adrenal cortex. In certain aspects, provided are methods of reducing the size of a tumor and/ or reducing a tumor-associated fluid accumulation using a composition comprising nanoparticles comprising an mTOR inhibitor (such as sirolimus) and an albumin.

THERAPEUTIC POTENTIAL OF CURCUMIN-CYCLODEXTRIN-CELLULOSE NANOCRYSTALS IN THE TREATMENT OF PERIPHERAL NEUROPATHIES

Resumen de: EP4570261A2

L'invention concerne un complexe comprenant :- des nanocristaux de cellulose ;- au moins une molécule de β-cyclodextrine ;- au moins une molécule de curcumine,pour une utilisation dans le traitement de tout type de neuropathies périphériques. L'invention concerne également une composition pharmaceutique comprenant au moins ledit complexe et au moins un excipient pharmaceutiquement acceptable. L'invention concerne en outre l'utilisation du complexe ou de la composition pharmaceutique, sous la forme notamment d'hydrogel, d'implant sous-cutané, de pompe implantable, de conduit nerveux biofonctionnalisé implanté, pour améliorer l'observance du traitement, permettre une libération prolongée du complexe et obtenir une meilleure pharmacocinétique.

METHODS AND COMPOSITIONS FOR TARGETED DELIVERY BY POLYMERSOMES

Resumen de: TW202502301A

The present disclosure relates to a copolymer and a polymersome for targeted delivery of biomolecules to a living organism. The exemplary copolymer comprises an initiator block, a propagator block, and a linkage connecting the initiator block and the propagator block. The initiator block comprises a glycan head configured to provide a targeted delivery, and the propagator block comprises a functional moiety configured to provide desired properties for the polymersome.

LIPID PARTICLE

Resumen de: EP4570269A1

An object of the present invention is to provide a lipid particle that can be produced without using a PEG-modified lipid, or that exhibits higher drug effects, safety, or stability than those of a lipid particle produced using a PEG-modified lipid; or that has immunokinetics different from those of a lipid particle produced using a PEG-modified lipid.A lipid particle comprising an ionized lipid, a phospholipid, and a sterol as lipid components of the lipid particle, and a modified polysaccharide containing a hydrophobic group.

ORAL FILM WITH MODERATE NICOTINE RELEASE AND PREPARATION METHOD THEREFOR

Resumen de: EP4570237A1

The present application discloses an oral film with moderate nicotine release and a preparation method thereof. The method includes the following steps: preparing a solution of hydroxypropyl chitosan and a solution of polyanion with a nicotine salt to obtain a mixed solution, adding the mixed solution into the hydroxypropyl chitosan solution to obtain a suspension of nicotine salt nanoparticles, and centrifugally drying to obtain nicotine salt nanoparticles; preparing a film-forming solution, adding the nicotine salt and nicotine salt nanoparticles into the film-forming solution according to a compound ratio, and drying to produce a film, thus obtaining an oral film with moderate nicotine release; and the compound ratio of the nicotine salt and the nicotine salt nanoparticles is 1: (0.5-3). The preparation method of the application is straightforward, and the oral film with moderate nicotine release has good mechanical properties and good sustained release effect

NOVEL ANTIGENS FOR CANCER AND USES THEREOF

Resumen de: AU2023322307A1

Breast cancer is now the most prevalent cancer worldwide, and despite therapeutical advances in the last decades, metastatic breast cancer remains an incurable disease. Novel tumor-specific antigens (TSAs) and tumor-associated antigens (TAAs) expressed by breast tumor cells are described herein. Synthetic long peptides, nucleic acids, compositions, cells, TCRs, antibodies and vaccines derived from these TSAs and TAAs are described. The use of the TSAs/TAAs, nucleic acids, compositions, antibodies, cells and vaccines for the prevention or treatment of breast cancer, including triple-negative breast cancer (TNBC), is also described.

POLYMER CONTRAST AGENT

Resumen de: EP4570837A1

The present invention relates to a copolymer in which a chelating agent molecule is bonded to a copolymer X comprising structural units of (A), (B), and (C).R¹, R², and R³ are the same or different and represent hydrogen or C_1-3 alkyl, R⁴ represents C_1-3 alkyl, R⁵ represents hydrogen, C_1-18 alkyl, 3- to 8- membered cycloalkyl optionally having substituent, adamantyl, C_6-18 aryl optionally having substituent, or 5- to 10- membered heteroaryl group optionally having substituent, X¹, X², and X³ are the same or different and represent oxygen, sulfur, or N-R⁷, R⁶ represents hydrogen, leaving group, or linker, R⁷ represents hydrogen or C_1-3 alkyl group, m represents 1 to 100, and n represents 0 to 3.

NOVEL COPOLYMER

Resumen de: EP4570835A1

To provide a novel copolymer utilizable for drug delivery technology.The present invention relates to a copolymer in which a target-affinity molecule is bonded to a copolymer X having structural units of (A), (B), and (C).R¹, R², and R³ are the same or different and represent hydrogen or C_1-3 alkyl; R⁴ represents C_1-3 alkyl; R⁵ represents hydrogen, C_1-18 alkyl, 3- to 8- membered cycloalkyl optionally having substituent, adamantyl, C_6-18 aryl optionally having substituent, or a 5- to 10- membered heteroaryl optionally having substituent; X¹, X², and X³ are the same or different and represent oxygen, sulfur, or N-R⁷; R⁶ represents hydrogen, leaving group, or linker; R⁷ represents hydrogen or C_1-3 alkyl; m represents 1 to 100; and n represents 0 to 3.

NEW DRUG COMPLEX

Resumen de: EP4570272A1

A novel copolymer utilizable for drug delivery technology.The present invention relates to a drug complex in which a target recognition molecule is bonded to a copolymer X comprising structural units of (A), (B), and (C) .R¹, R², and R³ are the same or different and represent hydrogen or C_1-3 alkyl, R⁴ represents C_1-3 alkyl, R⁵ represents hydrogen, C_1-18 alkyl, 3- to 8- membered cycloalkyl optionally having substituent, adamantyl, C_6-18 aryl optionally having substituent, or 5- to 10- membered heteroaryl group optionally having substituent, X¹, X², and X³ are the same or different and represent oxygen, sulfur, or N-R⁷, R⁶ represents hydrogen, leaving group, or linker, R⁷ represents hydrogen or C_1-3 alkyl group, m represents 1 to 100, and n represents 0 to 3.

METAL-PHOSPHOLIPID COMPLEX, METAL-PHOSPHOLIPID COMPLEX PARTICLE, DRUG-LIPID PARTICLE, METHOD FOR PREPARING SAME, AND USE THEREOF

Resumen de: EP4570271A1

The present disclosure provides a metal-chelated phospholipid complex, a metal-chelated phospholipid complex nanoparticle and a drug-lipid particle, and preparation methods and uses thereof, which relates to the field of biotechnology. The metal-chelated phospholipid complex is formed by reaction of a phospholipid molecular moiety, a linker molecular moiety, and a metal ion moiety. The metal-chelated phospholipid complex nanoparticle comprises a metal-chelated phospholipid complex, a particle aggregation-inhibiting conjugated lipid, and a non-cationic lipid or a non-ionizable lipid. The drug-lipid particle comprises a drug and the metal-chelated phospholipid complex nanoparticle. The metal-chelated phospholipid complex has a function in adsorbing drugs with negative charges and self-assembling with other lipids into metal-chelated phospholipid complex nanoparticles (MPP), so as to avoid the use of cationic lipid or ionizable lipid under the condition of ensuring the effectiveness which is not less than that of LNP, so that the toxicity of the drug-lipid particle is greatly reduced compared with LNP, the biological safety is remarkably improved, and the delivery of drugs with negative charges in organisms is facilitated.

SHRINKING NANOMATERIAL FOR BIOMEDICAL APPLICATIONS

Resumen de: WO2024035784A1

A size-changing nanoparticle construct for biomedical applications, and methods to fabricate and use such nanoparticle constructs.

一种用于治疗肝细胞癌的药物及应用

Resumen de: CN120154636A

本发明公开了一种用于治疗肝细胞癌的药物及应用。本发明首先构建了硒基纳米颗粒Se/ZIF8，所述硒基纳米颗粒由Se和ZIF8组成。将该硒基纳米颗粒与NK细胞共同处理肝癌细胞，可显著增强NK细胞对肝癌细胞的杀伤活性。同时，将该硒基纳米颗粒与NK细胞共同处理原位肝癌荷瘤小鼠，可显著提升NK细胞的抑瘤效果，起到了协同增效的作用。本发明为治疗肝癌提供了新的免疫药物选择，在肝癌的临床治疗中具有广阔的应用前景。

编码水痘-带状疱疹病毒糖蛋白E的mRNA疫苗

Resumen de: CN120158462A

本申请提供了一种编码水痘‑带状疱疹(VZV)糖蛋白E(gE)或其变异体的RNA，所述RNA包含与SEQ ID NO:11‑18中任一项所示的核苷酸序列具有至少80％、至少85％、至少90％、至少95％、至少96％、至少97％、至少98％或至少99％同一性的核苷酸序列。本申请提供的八种mRNA能在细胞内翻译，产生的VZV gE蛋白表达水平高，该mRNA经由脂质体纳米颗粒包封后形成的制剂通过肌肉注射到小鼠体内的方式，可诱导小鼠产生高滴度的gE特异性IgG抗体。

一种Aβ11和T80双配体修饰的核-壳纳米粒、制备方法及其用途

Resumen de: CN120154584A

本发明属于生物医药领域，具体涉及一种Aβ11和T80双配体修饰的核‑壳纳米粒、制备方法及其用途。本发明的主要技术方案是提供了包括包载药物的聚合物纳米粒核、包裹于聚合物纳米粒核表面的脂质材料，脂质材料加入Aβ11和T80进行修饰。本发明公开的双配体修饰的核‑壳纳米粒，在粒径、电位、包封率数据方面优异，有利于纳米粒药物的递送；稳定性更佳，更有利于所包载的药物的运输和储藏；具有显著的穿透血脑屏障，具有显著更佳的抗菌效果；药代动力和药效动力以及安全方面效果显著，在颅内抗感染方面具有非常好的应用前景。

一种双配体修饰的纳米递送系统

Resumen de: CN120154583A

本发明属于生物医药领域，具体涉及一种双配体修饰的纳米递送系统。本发明的主要技术方案是提供了包括包载药物的聚合物纳米粒、包裹于聚合物纳米粒表面的脂质材料，其中，脂质材料加入Aβ11和T80进行修饰。本发明公开的双配体修饰的纳米递送系统，得到的核‑壳纳米粒(Aβ11/T80@CSs‑药物)在粒径、电位、包封率数据方面优异，有利于纳米粒药物的递送；稳定性更佳，更有利于所包载的药物的运输和储藏；具有显著的穿透血脑屏障，具有显著更佳的抗菌效果；在颅内抗感染方面具有非常好的应用前景。

メッセンジャーＲＮＡの組成物、方法および使用

Resumen de: US2025057765A1

The present invention provides, among other things, methods and compositions for cancer treatment. The methods and compositions disclosed herein are particularly effective in reducing the size/volume of a tumor and inhibiting tumor growth.

合成メッセンジャーＲＮＡによる原発性繊毛機能不全症の治療

Resumen de: AU2025202461A1

Polynucleotides encoding peptides, proteins, enzymes, and functional fragments thereof are disclosed. The polynucleotides of the disclosure can be effectively delivered to an organ, such as the lung, and expressed within cells of the organ. The polyribonucleotides of the disclosure can be used to treat a disease or condition associated with cilia maintenance and function, impaired function of the axoneme, such as DNAIl or DNAH5.

一类BODIPY染料及其在光热领域的应用

Resumen de: CN120157696A

一类BODIPY染料及其在光热领域的应用，其属于功能染料及生物医药的技术领域。在一般氟硼类二吡咯亚甲基染料的基础上修饰以强吸电子基团三氟甲基，经对羟基苯甲醛修饰延长共轭结构后，使其吸收波长发生了显著红移；后单侧羟基与对甲苯磺酰氯反应，得到该BODIPY染料。在经两亲性分子DSPE‑PEG2000包裹后形成纳米颗粒，结合zeta电位为负的特征，该BODIPY染料能够靶向肿瘤细胞溶酶体，然后实现溶酶体逃逸，并最终靶向内质网。这使得该BODIPY染料即使是在较温和的光热条件下进行光热治疗，也能够引起内质网应激，诱导肿瘤细胞发生免疫原性死亡，有效的杀死肿瘤细胞。本发明中BODIPY染料合成方式简单、暗毒性低、细胞杀伤效果好，具有应用于临床治疗的潜力。

Nanoparticules radioactives de type cœur/enveloppe utiles en radiothérapie ciblée

Resumen de: FR3156311A1

La présente invention concerne une nanoparticule radioactive de type cœur/enveloppe comprenant : - un cœur à base de silice poreuse comprenant un ou plusieurs radionucléide(s) émetteur(s) α et un ou plusieurs radionucléide(s) émetteur(s) β, et - une enveloppe métallique. La présente invention concerne également l’utilisation de cette nanoparticule radioactive comme médicament, notamment dans la prévention et/ou le traitement du cancer, et/ou comme agent d’imagerie.

신규 이온화 가능한 지질

Resumen de: AU2023361218A1

The present invention relates to compounds of formula (I). The invention also extends to micro- or nanoparticles comprising a compound of formula (I). For instance, compounds of formula (I) can be used to produce stable lipid nanoparticles (LNPs). The LNPs have high encapsulation efficiency and can be used to deliver a therapeuticor prophylactic agent to a patient.

Anticancer composition containing gold-nanorods combined with glucuronic acid

Resumen de: KR20250086122A

본 발명은 글루쿠론산 결합 금나노로드 및 이를 포함하는 항암용 조성물에 관한 것으로서, 상기 금나노로드는 암세포 선택적으로 세포 내 이온 불균형을 일으키고, Caspase-3/7 활성화, 아폽토시스, 활성산소 발생을 유도함으로써 암세포의 세포막 변형을 일으켜 암치료에 효과적임을 제시한다.

DNA Prussian blue nano particles coated with Salmon-derived DNA and use thereof

Resumen de: KR20250085875A

본 발명은 연어유래 DNA 코팅 프러시안 블루 나노입자 및 이의 용도에 관한 것이다. 보다 구체적으로, 본 발명은 연어유래 DNA로 코팅된 프러시안 블루 나노입자 및 이의 용도, 예를 들면 항산화제, 항염증제, 약제학적 조성물, 의약외품 조성물, 화장료 조성물 또는 식품 조성물에서의 용도에 관한 것이다.

靶向细胞核的基因编辑递送载体、纳米颗粒以及制备方法和应用

Nº publicación: CN120131974A 13/06/2025

Solicitante:

厦门大学

Resumen de: CN120131974A

本发明涉及一种基因编辑递送载体、递送系统及其制备方法和应用。该载体为利用苯硼酸对线性聚乙烯亚胺改性制得获得的细胞核靶向高分子载体。利用该载体制备的纳米颗粒和纳米递送系统，无需进行额外的传统核定位序列(NLS)肽修饰，即可具有超高的细胞核靶向能力，能够在活细胞及体内水平进行高效的基因编辑，并在细胞核区域对目的基因进行实时成像，显著提高了活细胞和体内基因编辑的效率和核酸检测的准确性。同时具有易于制备、基因编辑效率高、检测灵敏度高等优点。